Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Stomach Neoplasms 1 Solid Tumor Spine Metastases 1 Sarcoma 1 Rectal Neoplasms 1 Oligodendroglioma 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms 1 Lymphoma, Follicular 1 Locally Advanced Colon Cancer 1 Head and Neck Neoplasms 1 Glioma 1 Glioblastoma 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Astrocytoma 1 Anxiety Disorders 1 Amenorrhea 1

Interventions

Cisplatin 258 Radiotherapy 193 Cetuximab 151 pembrolizumab 123 Docetaxel 97 Fluorouracil 92 Carboplatin 80 Paclitaxel 78 Radiotherapy, Intensity-Modulated 72 Surveys and Questionnaires 46 Nivolumab 42 Drug Therapy 34 Radiation 33 Blood Specimen Collection 27 Erlotinib Hydrochloride 26 Gemcitabine 25 Immunohistochemistry 22 Gefitinib 22 Cyclophosphamide 22 Surgical Procedures, Operative 21 Standard of Care 20 durvalumab 19 Pemetrexed 19 Magnetic Resonance Spectroscopy 19 Radiosurgery 17 Capecitabine 17 Chemotherapy, Adjuvant 16 Celecoxib 16 Biopsy 16 atezolizumab 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Head and Neck Neoplasms × Postoperative Period × Clear all

NCT02435576 2024-04-15

H&NTOX

University Medical Center Groningen

10,000 enrolled

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡